Related Experiment Videos
Positron emission tomography imaging of transplant function.
1Medical Research Council Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 ONN, United Kingdom. david.brooks@mrc.ac.uk
Summary
Functional imaging, including PET and SPECT, can show fetal tissue survival in Parkinson's and Huntington's disease patients. However, these methods are not yet suitable as primary outcome measures for clinical trials.
Area of Science:
- Neuroscience
- Medical Imaging
- Neurological Disorders
Background:
- Parkinson's disease (PD) and Huntington's disease (HD) are debilitating neurodegenerative disorders.
- Fetal tissue transplantation is a potential therapeutic strategy for PD and HD.
- Assessing graft survival and integration is crucial for evaluating therapeutic efficacy.
Purpose of the Study:
- To review the utility of functional imaging techniques in evaluating fetal tissue grafts in PD and HD patients.
- To discuss the dissociation between imaging findings, clinical outcomes, and dopamine storage.
- To explore mechanisms of dyskinesias in the context of these therapies.
Main Methods:
- Review of functional imaging studies (PET and SPECT) in patients with PD and HD undergoing fetal tissue transplantation.
- Analysis of correlations between imaging data, clinical assessments, and dopamine metabolism.
- Examination of potential mechanisms for medication-off dyskinesias.
Main Results:
- Functional imaging provides objective evidence of fetal graft survival and neural connections.
- Observed dissociation between dopamine storage, clinical improvement, and normalized brain metabolism in PD.
- Dyskinesias off medication may arise from complex interactions within the grafted and host neural circuitry.
Conclusions:
- Positron emission tomography (PET) and single photon emission computed tomography (SPECT) offer valuable supplementary data.
- Current functional imaging modalities are not appropriate as surrogate endpoints for clinical trials in PD and HD.
- Further research is needed to refine imaging biomarkers for assessing therapeutic outcomes.